Study and analysis of maternal serum alpha-fetoprotein levels as a biomarker of placental adherence in low lying placenta
DOI:
https://doi.org/10.18203/2320-6012.ijrms20231340Keywords:
Low lying placenta, MSAFP, Placental adherenceAbstract
Background: The objective was to study and analyze maternal serum alpha-fetoprotein levels as a biomarker of placental adherence in low lying placenta.
Methods: This was a prospective observational study analysing the conditions and the data of 80 cases with low lying placenta in a tertiary care hospital. The analysis was done for the association of MSAFP with MRI, perinatal and maternal outcome.
Results: The level of MSAFP was found higher in 12 out of 13 cases (93.3%) of placenta previa with placental adherence. There was significant surgical intervention (80%) and increased maternal morbidity (68.8%) in the study group with placental adherence and raised MSAFP respectively.
Conclusions: MSAFP is an important biomarker for prognostication of placental adherence in low lying placenta.
References
Martin JA, Hamilton B E, Sutton PD et al. Birth final data for 2003. National vital statistics report. 2005;54(2):97-9.
Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDV, et al. Obstetrical hemorrhage. In: Williams Obstetrics, 20th ed. Appleton & Lange: Stamford. 1997:755-6.
Silver, Robert M, Landon Mark B. Maternal morbidity associated with multiple repeat cesarean delivery. Obstet Gynecol. 2006;107(6):1226-32.
Al-Serehi A, Mhoyan A, Brown M, Benirschke K, Hull A, Pretorius DH. Placenta accreta: an association with fibroids and Asherman syndrome. J Ultrasound Med. 2008;27:1623-28.
Hamar BD, Wolff EF, Kodaman PH, Marcovici I. Premature rupture of membranes, placenta increta, and hysterectomy in a pregnancy following endometrial ablation. J Perinatol. 2006;26:135-7.
Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Ontario UFE Collaborative Group. Obstet Gynecol. 2005;105:67-76.
Zelop C, Nadel A, Frigoletto FD Jr. Placenta accreta/precreta/ increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1992;80:693-94.
Kupferminc MJ, Tamura RK, Wigton TR. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1993;82:266-9.
Babinszki A, Kerenyi T. Perinatal outcome in grand and great grand multiparity. Effects of parity on obstetric risk factors. Am J Obstet Gynecol. 1999;181:669.
Ananth CV, Demissie K, Smulian JC. Placentanprevia in singleton and twin births in the United States, 1989 through 1998. A comparison of risk factor profiles and associated conditions. Am J Obstet Gynecol. 2003;188:275.
Lala ABH, Rutherford JM. Massive or recurrent ante partum haemorrhage. Current Obstet Gynaecol. 2002;12:226-30.
Verma P, Singh KN, Ghanghoriya V. To study analyze maternal serum alpha-fetoprotein as a biomarker of placental adherence in low lying placenta. Int J Reprod Contracept Obstet Gynecol. 2016;5(6):1959-63.
Butler EL, Ronald MM. Association between Maternal Serum Alpha Fetoprotein and Adverse Outcomes in Pregnancies With Placenta Previa. Obstet Gynecol. 2001;97(1):35-38.